The company has transitioned from a defunct dairy and pharma nutrition business into a real estate developer focused on residential and commercial projects, primarily targeting the Mumbai redevelopment market.
The company currently possesses no identifiable moat; it is a new entrant in a highly competitive and capital-intensive real estate market with no track record of project completion or unique land bank advantages. Financial metrics show negative margins and low returns on capital, contradicting any narrative of competitive advantage.
Historically, the company held cash in fixed deposits while its core dairy operations were dormant; under new management, capital is being redirected toward real estate project evaluation and inter-corporate loans, though no value-generating projects have yet broken ground.
The company's pivot from dormant dairy operations to real estate proved to be a value-destroying mirage. The 13.5 crore loan to a related party was never recovered, and the capital intended for development was instead consumed by high executive salaries and administrative overhead. Without a track record or land bank, the firm failed to break ground on any viable projects, eventually depleting its cash reserves while the untraceable assets from the previous regime signaled a permanent culture of poor internal controls.
RichFakir rates Lake Shore Realty Ltd's business quality as poor — 15/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Lake Shore Realty Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Lake Shore Realty Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Lake Shore Realty Ltd's fair value is about ₹11 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →